Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms CLEAR MIND
- Sponsors Longeveron
- 15 Apr 2024 According to a Longeveron media release, results from this trial has been selected for presentation at the 2024 Alzheimer's Association International Conference (AAIC), to be held July 28 - August 1, 2024 in Philadelphia, PA, USA and online.
- 08 Apr 2024 According to a Longeveron media release, company plans to present data from this Phase 2a CLEAR-MIND Study in Mild Alzheimers Disease patients at various scientific conferences and submit findings for publication.
- 16 Feb 2024 Status changed from active, no longer recruiting to completed.